

FOI 4850

FOI Request re Urothelial Cancer Patients

Please indicate the number of metastatic or locally advanced Urothelial¹ cancer patients treated² by your Trust in the 3 months, April 2018 to June 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated		Total Urothelial Cancer patients (any stage)	18
		Other (please specify)	
		Data not held/accessible	

Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive, please indicate the number treated with the following therapies.

Therapy	Total number treated (Metastatic/locally advanced Urothelial patients)	If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:	
Cisplatin (mono or combination therapy)		Total Urothelial Cancer patients (any stage)	0
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)		Total Urothelial Cancer patients (any stage)	0
		Other (please specify)	
		Data not held/accessible	

¹ ICD10 C65, C66, C67, C68; TNM staging for metastatic Urothelial Cancer = Any T, any N, M1; TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0; Please include numbers for:

- any diagnosis of metastatic disease as opposed to patients that present with metastases
- all metastatic sites from a Urothelial primary

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

FOI 4850

Pembrolizumab (Keytruda)		Total Urothelial Cancer patients (any stage)	0
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)		Total Urothelial Cancer patients (any stage)	0
		Other (please specify)	
		Data not held/accessible	

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

Please note our response relates to patients who started treatment between 01/04/2018 and 30/06/2018, having diagnosis codes within the group C67 - Malignant neoplasm of bladder and SNOMED morphology codes M81203 - Transitional cell carcinoma or M81303 - Papillary transitional cell carcinoma.